The 5th International Electronic Conference on Cancers
The 5th International Electronic Conference on Cancers
Part of the International Electronic Conference on Cancers (IECC) series
Event's Timezone: Central European Summer Time
15 March 2026
12 April 2026
7 June 2026
Tumor Microenvironment, Inflammation, Biomarkers, Theranostics, Artificial Intelligence, High-throughput-screening, Molecular Targeting, Cell Plasticity, Personalized Medicine
Registrations are Open till 7th June 2026. Register for Free HERE.
We will notify you about your abstract presentation type by 31 May 2026 .
Please check your email frequently to avoid missing notifications. Thank you for your patience.
Welcome from the Chair
Laboratory of Cancer Stem Cell Engineering, Okayama University, Okayama, Japan
More News about MDPI Conferences
Program Overview
IECC 2026 Program (Day 1)
10th June - Morning
IECC 2026
Session 4. Cancer Survivorship and Quality of Life
Date: 10th June 2026 (Wednesday)
Time: 09:00 (CEST, Basel) | 03:00 (EDT, New York) | 15:00 (CST Asia, Beijing)
10th June - Morning
IECC 2026
Session 1. Cancer Stem Cells
Date: 10th June 2026 (Wednesday)
Time: 11:05 (CEST, Basel) | 5:05 (EDT, New York) | 17:05 (CST Asia, Beijing)
10th June - Afternoon
IECC 2026
Session 3. Drug Resistance and Anti-cancer Drug Development and Screening
Date: 10th June 2026 (Wednesday)
Time: 14:00 (CEST, Basel) | 8:00 (EDT, New York) | 20:00 (CST Asia, Beijing)
IECC 2026 Program (Day 2)
11th June - Morning
IECC 2026
Session 7. Novel Methods and Technologies for Research and Treatment
Date: 11th June 2026 (Thursday)
Time: 09:00 (CEST, Basel) | 03:00 (EDT, New York) | 15:00 (CST Asia, Beijing)
11th June - Morning
IECC 2026
Session 7. Novel Methods and Technologies for Research and Treatment
Date: 11th June 2026 (Thursday)
Time: 14:00 (CEST, Basel) | 08:00 (EDT, New York) | 20:00 (CST Asia, Beijing)
IECC 2026
Session 2. Tumor Heterogeneity
Date: 11th June 2026 (Thursday)
Time: 15:30 (CEST, Basel) | 9:30 (EDT, New York) | 21:30 (CST Asia, Beijing)
IECC 2026 Program (Day 3)
12th June - Morning
IECC 2026
Flash Poster Session
Date: 12th June 2026 (Friday)
Time: 09:00 (CEST, Basel) | 03:00 (EDT, New York) | 15:00 (CST Asia, Beijing)
12th June - Morning
IECC 2026
Session 5. Causes, Diagnosis and Treatment of Cancer
Date: 12th June 2026 (Friday)
Time: 10:30 (CEST, Basel) | 04:30 (EDT, New York) | 16:30 (CST Asia, Beijing)
12th June - Afternoon
IECC 2026
Session 5. Causes, Diagnosis and Treatment of Cancer
Date: 12th June 2026 (Friday)
Time: 14:00 (CEST, Basel) | 08:00 (EDT, New York) | 20:00 (CST Asia, Beijing)
Abstract Book
Event Chair
Laboratory of Cancer Stem Cell Engineering, Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, Japan Website
Masaharu Seno graduated Osaka university in Japan and awarded Bachelor of Engineering in 1981. He worked for Takeda Chemical Industries, Ltd., Osaka, Japan as a Staff Scientist from 1981 to 1992. In this period, he was awarded Ph.D. on the thesis of fibroblast growth factor from Osaka University. Then, he moved to the Faculty of Engineering, Okayama University, Okayama, Japan engaged in protein engineering, nano-biotechnology and stem cell engineering including cancer stem cells from 1992 to 2022. From 1995 to 1996 and from 2000 to 2001, he stayed National Cancer Institute, NIH in the US as a guest scientist. Notably, he converted induced pluripotent stem cells into cancer stem cells in 2012 for the first time in the world. He was awarded Professor Emeritus from Okayama University in 2022 and is currently a professor of cancer stem cell engineering in the Faculty of Interdisciplinary Science and Engineering in Health Systems at the same university since 2022.
Session Chairs
Prof. Dr. Angeliki Magklara
1. Laboratory of Clinical Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece; 2. Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina, Greece
Professor Angeliki Magklara is a faculty member at the Faculty of Medicine, University of Ioannina, Greece, and Director of the Biochemistry (Clinical Chemistry) Laboratory at the University Hospital of Ioannina. Her research focuses on cancer biology, with particular emphasis on cancer stem cells, chemoresistance, and liquid biopsy biomarkers. By integrating multi-omics approaches, her research group investigates mechanisms of therapeutic resistance, especially in breast cancer. Prof. Magklara has authored numerous peer-reviewed publications, serves on international scientific review panels and journal editorial boards, and is actively involved in clinical diagnostics, medical education, and translational research initiatives.
Prof. Dr. Sebastiano Mercadante
Main Regional Center for Pain Relief & Palliative Care Unit, La Maddalena Cancer Center, Palermo, Italy
Sebastiano Mercadante, born on 3rd December 1955, - Doctor's degree (Medicine & Surgery), 1973-1979 with full marks, 110/110 cum laude, University of Palermo. - Specialization in Anesthesiology (1980-1983), and Science of Nutrition (1984-1987), University of Palermo. - National abilitation for Full Professor of Anesthesiology, Intensive Care, and Pain Therapy - Director of Main regional center for Pain Relief & Palliative/Supportive Care Unit, La Maddalena, Palermo, Italy - Scientific Director, Regional home palliative care program SAMOT - More than 700 lectures at national and international congresses. - Associated Editor, editorial Board and/or referee of more than 40 international peer-reviewed journals in the field of pain and symptom management, palliative care, and anesthesiology - More than 500 papers published in peer-reviewed international journals, including Lancet, Lancet Oncol, J Clin Oncol, Ann Oncol, Eur J Oncol, Anesthesiology, J Pain Symptom Manage, Palliat Med. H-index = 89 (Google Scholar). - Author of more than 40 chapters and books. - Award Umberto Veronesi 2003 - Award of excellence in scientific research, American Academy of Hospice and palliative medicine, Boston 2010 - Award John Mendelson MD, University of Texas MD Anderson cancer center “for extraordinary contribution in palliative care” Houston, 11-12 October 2013. - Award for International Clinical Impact. EAPC Rotterdam June 2023 - Patent for “new delivery system for analgesics”. N.21596IT/EL/FG/EM - Since 1st December 2016, Adjunct professor of palliative medicine, MD Anderson, University of Texas, Houston, TX, USA - 2018-2021. Member of the national ministerial commission for pain and palliative care. - 2022-2021. First expert around the world on “cancer pain” and breakthrough pain” (expert.com) - Chair of “palliative care” subgroup of MASCC, since June 2024
Prof. Dr. Ajay Pratap Singh
Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, USA
Dr. Ajay Singh is a tenured Professor of Cell and Molecular Biology and Vice Chair in the School of Medicine at the University of Mississippi Medical Center. He is also the Associate Director of Basic and Translational Research at the Cancer Center and Research Institute. His laboratory focuses on identifying novel tumor-associated genes and how they affect tumor cell behavior. His lab is also interested in understanding how tumor cells communicate with their surroundings to become more aggressive and therapy-resistant, and whether targeting these tumor-stromal interactions could be exploited for cancer prevention and therapy. Another focus is to understand molecular differences in tumors from patients of different racial and ethnic backgrounds and to investigate their roles in disparate clinical outcomes. He has published extensively, holds multiple US patents, and is a co-founder of a small Biotech company, Tatva Biosciences. He has received numerous honors and awards for his scientific and scholarly accomplishments and has received funding from major federal agencies, including NIH, DOD, and NSF, as well as from the state health departments and private foundations. He also actively serves on national and international grant study sections and is a member of the editorial boards of several scientific journals.
Prof. Dr. Henry H. Heng
Center for Molecular Medicine and Genomics, Pathology Department, Wayne State University School of Medicine, Detroit, MI, USA
Dr. Farrukh Aqil
Department of Medicine, University of Louisville, Louisville, USA
Farrukh Aqil, Ph.D., is an Associate Professor in the Department of Medicine and a member of the Brown Cancer Center at the University of Louisville. His research focuses on exosome-based delivery of small molecules and nucleic acids for cancer therapy, with particular emphasis on translational nanomedicine and targeted therapeutics. Dr. Aqil has authored more than 100 peer-reviewed publications and holds multiple U.S. patents. He is actively involved in mentoring graduate students, postdoctoral fellows, and junior investigators, and is committed to fostering collaborative research environments. He also serves on editorial boards of various journals, and as an ad hoc reviewer for NIH and NSF study sections.
Professor. Nicola Amodio
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
Nicola Amodio earned a PhD in Molecular Oncology in 2007 and a specialization in Applied Pharmacology in 2011 at the University Magna Graecia of Catanzaro, Italy. He was a Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center, New York, from 2006 to 2007. From 2008 to 2018, he worked as Research Fellow and Research Assistant at the University Magna Graecia of Catanzaro with support from AIRC, the Umberto Veronesi Foundation, and the Lilli Funaro Foundation. Since 2019 he has been a tenure track researcher, and since 2022 Associate Professor of Pathology at the same university. He has co-authored over 150 international publications, received awards from institutions including ASH and the Umberto Veronesi Foundation, and has been listed among the Top Italian Scientists by VIA Academy since 2019. He is Section Editor-in-Chief of Cancers. His research focuses on identifying novel therapeutic targets in cancer through integrated transcriptomic, epigenomic, and functional preclinical approaches.
Prof. Dr. Ewa Koscielniak
Medical Faculty, University of Tübingen, Tubingen, Germany
Prof. Dr. Andrew A. Gumbs
1. Department of Minimally Invasive Digestive Surgery, Antoine-Béclère Hospital, Greater Paris University Hospitals, Clamart, France; 2. Department of Surgery, Otto von Guericke University Magdeburg, Magdeburg, Germany
Professor Gumbs is the Director of Artificial Intelligence Surgery at the Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris. He is the Editor-in-Chief of Artificial Intelligence Surgery (aisjournal.net) and is the Chief Medical Officer of ACCREA Medical Robotics, which specializes in collaborative interventional robotics. He is also the President and founder of the Artificial Intelligence Organization for the Next generation of Surgeons (AIONS.ai). Professor of Surgery at Grigol Robakidze University and the University of Magdeburg, he was previously Director of the Minimally Invasive Hepatic-Pancreatic-Biliary Surgery Program at SMG-MD Anderson Cancer Center and prior to that the Director of Minimally Invasive Hepatobiliary Surgery and at Fox Chase Cancer Center in Philadelphia, Pennsylvania. He has been Instructor of Clinical Surgery at Cornell-Weill Medical College, Instructor of Clinical Surgery at Columbia University College of Physicians and Surgeons, and Assistant Professor of Surgery in the Department of Surgical Oncology at Fox Chase Cancer Center. He is certified in general surgery, hepatic-pancreatic and biliary surgery, robotic and in laparoscopic surgery. He has delivered local, regional, national, and international invited presentations primarily devoted to minimally invasive surgical techniques for the liver, pancreas, and digestive organs and artificial intelligence surgery. His articles have been published in Annals of Surgery, Surgery, Journal of the American College of Surgeons and the Proceedings of the National Academy of Science. He has volunteered for Doctors Without Borders in the Democratic Republic of the Congo and Haiti and has also done several humanitarian missions to Ecuador.
Prof. Dr. Guo-Min Li
Institute for Cancer Research, Chinese Institutes for Medical Research, Beijing, China
Guo-Min Li is Director and Distinguished Investigator at the Chinese Institute for Cancer Research, CIMR, Beijing. He received his B.A. from Wuhan University and Ph.D. from Wayne State University. He trained with Nobel laureate Paul Modrich at Duke, discovering that DNA mismatch repair (MMR) defects cause cancer. Before returning to China in 2023, he held an endowed chair at UT Southwestern. His research links MMR to cancer and neurodegenerative diseases. He reconstituted human MMR in vitro, revealed epigenetic regulation, explained how MMR-deficient tumors respond to immunotherapy via activating the cGAS-STING pathway, and uncovered MMR’s role in driving DNA repeat expansion underlying neurodegeneration.
Committee Members
Department of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, USA
Department of Ophthalmology, University of Padova, Padova, Italy
Second Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
ReGenera R&D International for Aging Intervention and San Babila, Clinic, Vitality Therapeutics, Milano, Italy
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Pokfulam, Hong Kong
Department of Biochemistry and Molecular Biology, University of New Mexico, Albuquerque, USA
Department of Radiation Oncology, University of Michigan, Ann Arbor, USA
Department of Radiology Oncology, Centre De Haute Energie, Nice, France
School of Women’s & Children’s Health, University of New South Wales, Sydney, Australia
Department of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary
Section of Hematology/Oncology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, USA,
The Department of Microbiology and Molecular Genetics, The University of Pittsburgh School of Medicine, Pittsburgh, USA,
The Hillman Cancer Center, The University of Pittsburgh Medical Center, Pittsburgh, USA,
The University of Pittsburgh Liver Research Center, The University of Pittsburgh Medical Center, Pittsburgh, USA
Department of Life Sciences, Link Campus University, Rome, Italy
Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, USA
Medical Oncology Department, Research Center Cancer Biology & Epigenetics Group and Clinical Trials Department, Institito Portugues de Oncologia do Porto (IPO-Porto), Porto, Portugal
Cancer League of Eastern Switzerland, Flurhofstrasse 7, St. Gallen, Switzerland
University of New Mexico Health Sciences Center, United States
Department of Pathology, New York University Grossman School of Medicine, New York, USA
Department of Immunology and Oncology, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain
Department of Radiology and Imaging, University of Texas Medical Branch at Galveston, Galveston, USA
Nationwide Children’s Hospital Institute for Genomic Medicine and The Ohio State University College of Medicine Depts of Pathology and Pediatrics, Columbus, Ohio USA
Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Department of Pharmacy, University “G. d’Annunzio”, Chieti, Italy
Department of Biochemistry,Monash Biomedicine Discovery Institute, Monash University, Australia
Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, MD, USA
Keynote Speakers
Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX，USA
Polyploid Giant Cancer Cells as a Window into Tumor Heterogeneity
Dr. Jinsong Liu received his PhD in Biochemistry from Case Western Reserve University and completed postdoctoral training at the Howard Hughes Medical Institute and the University of Michigan, followed by a pathology residency and surgical pathology fellowship at New York University. He joined MD Anderson Cancer Center in 1999. Over the past 26 years, Dr. Liu has been an active member of MD Anderson's world-renowned gynecologic diagnostic pathology team. He has authored more than 300 scientific publications in high-impact journals. Dr. Liu's laboratory made the unexpected discovery that polyploid giant cancer cells (PGCCs) — historically considered non-dividing or senescent — can dedifferentiate into blastomere-like pluripotent stem cell-like states, recapitulating early embryonic programs to generate drug-resistant and metastatic progeny. He chaired the inaugural International Conference on Polyploid Giant Cancer Cells in 2024, marking the formal establishment of this emerging field. His work provides a new conceptual framework for understanding cancer origin, therapeutic resistance, and their connections to fundamental developmental processes.
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI，USA
Cancer as a Supersystem: Chromosomal Instability Drives Multiscale Heterogeneity Through Two-Phased Evolution
Henry H.Q. Heng, PhD Professor of Molecular Medicine and Genetics and of Pathology Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI Dr. Heng received his PhD in Medical Genetics from the University of Toronto's Hospital for Sick Children, mentored by Dr. Lap-Chee Tsui, and completed postdoctoral training in chromosomal biology under Dr. Peter Moens at York University before joining Wayne State University School of Medicine in 1999. Over more than two decades of watching cancer evolution in action — tracing karyotype dynamics, transcriptomes, and phenotypes longitudinally through phase transitions — Dr. Heng developed the Genome Architecture Theory (GAT), a new information- and genome-based conceptual framework that fundamentally challenges the gene-centric paradigm of cancer research and evolutionary biology. Key contributions include the discovery of genome chaos, fuzzy inheritance, and two-phased cancer evolution — comprising a punctuated macroevolutionary phase dominated by genome chaos and a gradual microevolutionary phase dominated by gene mutation — a pattern commonly detected across all key transitions of cancer evolution, including transformation, metastasis, and drug resistance. Central to GAT is the concept of karyotype coding: the order of genes and genetic elements on chromosomes within the 3D genome constitutes a new layer of key genomic information, and system inheritance — defined by genome topology — represents the true blueprint of biological systems that organizes gene interaction networks. Dr. Heng's books, Genome Chaos: Rethinking Genetics, Evolution, and Molecular Medicine (Academic Press, 2019; 2nd ed. 2025) and Debating Cancer: The Paradox in Cancer Research, have attracted wide attention across the fields of cancer biology and evolutionary theory. He has authored over 200 peer-reviewed publications and serves on the editorial boards of seven international journals.
Invited Speakers
Department of Hepatobiliary-Pancreatic Surgery, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Intraoperative fluorescence imaging for cancer surgery
Professional Activities and Distinctions: Dr. Takeaki Ishizawa received his medical degree in 2000 from The University of Chiba, in Chiba Japan and then went on to complete his Ph.D. in 2008 at The University of Tokyo. In 2011, Dr. Ishizawa stayed in Paris as a fellow at the Institut Mutualiste Montsouris. Dr. Ishizawa performed more than 300 laparoscopic and open hepatobiliary and pancreatic surgeries at the Cancer Institute Hospital, Japanese Foundation for Cancer Research in Tokyo, between 2014 and 2017. Dr. Ishizawa had also participated in liver transplantation at the University of Tokyo Hospital. From April 2022, Dr. Ishizawa supervises hepatobiliary and pancreatic surgery using robot-assisted approach as a Professor of the Department of Hepatobiliary-Pancreatic Surgery at Osaka Metropolitan University. Areas of Research and Publication: Dr. Ishizawa has developed in vivo fluorescence imaging and actively applied these techniques to his clinical practices. So far, Dr. Ishizawa has been published for his work in hepatobiliary and pancreatic surgery and fluorescence-guided surgery in more than 80 peer-reviewed international journals, including the Gastroenterology and the Annals of Surgery. He also played a role as a president of the International Society for Fluorescence Guided Surgery (ISFGS, www.isfgs.org), aiming to share updated information on this topic among researchers, surgeons, and technicians. Dr. Ishizawa has been honored with many prestigious awards including: award from the 106th Annual Congress of Japan Surgical Society, the British Journal of Surgery Award at the 45th Congress of the European Society for Surgical Research, KARL STORZ Award at the 24th Annual Meeting of the Japan Society for Endoscopic Surgery, Best International Abstract Award at SAGES2016, and the 2017 International Guest Scholarship of American College of Surgeons.
Diagnosis and treatment of Multiple Myeloma
Medical Doctor Day Hospital Department of Hematology – A.O. Annunziata - Cosenza with expertise in Diagnosis and treatment of lymphoproliferative disorders (Hodgkin and non Hodgkin lymphomas, multiple myeloma) Expert on Lymphoproliferative Disorders in Università della Calabria
Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Development of Novel Drug Delivery Pathways Enabled by Perillyl Alcohol (NEO100), a Monoterpene with Multifaceted Biomedical Applications
Axel H. Schönthal, PhD, is Associate Professor in the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of the University of Southern California (USC) in Los Angeles. Before joining USC, he had obtained his PhD from the University of Karlsruhe, Germany, followed by a postdoctoral stay at the Cancer Center of the University of California in San Diego (UCSD), California. At USC, he pursues the development of novel anticancer agents and novel delivery methods to improve cancer therapeutic efficacy. As of 2026, he has authored over 200 scholarly articles and chapters with an H-Index of 54.
Emergency Medicine Department, University of Texas, MD Anderson Cancer Center, Houston, USA
When less is Actually more, Goals of Care for Patients with Advanced Cancer
Ahmed Elsayem, MD, is a Professor of Emergency Medicine and Palliative Care at The University of Texas MD Anderson Cancer Center in Houston. He received his medical degree from University of Khartoum and completed his Internal Medicine residency at Howard University Hospital, followed by a clinical fellowship in Palliative Care at MD Anderson. He also completed public health training at the UT School of Public Health. Dr. Elsayem has over two decades of experience in palliative and emergency cancer care, with a research focus on outcomes among patients with advanced cancer presenting to the emergency department. His work centers on symptom burden, delirium, and prognostic factors for short-term mortality, aiming to improve early integration of palliative care in acute settings. He has held multiple leadership roles, including Director of the Acute Palliative Care Unit and Founder and Chair of the Acute Supportive Care Committee in Emergency Medicine. His contributions have helped shape clinical practice and research in oncologic emergency care and palliative medicine.
Department of Surgical Oncology, MUL Medical Center, Medical University of Lublin, Poland
AI in Gastric Cancer
Karol Rawicz-Pruszyński, MD, PhD, is a Professor of Surgery, Surgeon-in-Chief of the Department of Surgical Oncology at University Clinical Hospital No. 1 in Lublin, and Vice-Dean of the Medical Faculty at the Medical University of Lublin, Poland. His clinical and academic expertise focuses on minimally invasive and robotic surgery, particularly in gastric, colorectal and hepatopancreatobiliary cancers, as well as hyperthermic intraperitoneal chemotherapy (HIPEC) and complex surgical oncology. He completed his medical degree, PhD, and habilitation at the Medical University of Lublin, Poland, with his scientific work centered on optimizing diagnostic and therapeutic pathways in advanced gastrointestinal cancers. In 2026, he was awarded the title of Professor by the President of the Republic of Poland. He has also completed international research fellowships at Erasmus MC in Rotterdam (the Netherlands) and The Ohio State University Wexner Medical Center in the United States. Professor Rawicz-Pruszyński is the Chairman of the Taskforce on Robotic Surgery and Artificial Intelligence at the Medical University of Lublin. His research output includes more than 85 scientific publications, an Impact Factor exceeding 335, and an h-index of 19. He has contributed to several national and international projects, including the GASTRODATA Registry and NCDB-based collaborations, with key publications in the fields of gastric cancer, textbook oncological outcomes, minimally invasive surgery and surgical oncology. In addition to his clinical and scientific work, he is actively involved in medical education, doctoral supervision, and editorial activities for international journals. His professional interests combine oncological surgery, robotic innovation, artificial intelligence, academic leadership, and translational research to improve outcomes for patients with gastrointestinal cancers.
Quality of life and psychosocial wellbeing in older women with primary breast cancer
Kwok-Leung Cheung is Professor of Breast Surgery and Medical Education, and Deputy Head of Education and Director of The BMBS Medicine Programmes at the University of Nottingham, with clinical and research interests in breast cancer and geriatric oncology. He is the President-Elect of the International Society of Geriatric Oncology, a member of the Executive Committee of the European Society of Breast Cancer Specialists, and of the Breast Cancer Clinical Guidelines Committee and the Expert Adviser Panel of the National Institute for Health and Care Excellence. Professor Cheung pioneered the Symposium on Primary Breast Cancer in Older Women in the UK.
Sessions
S2. Tumor Heterogeneity
S3. Drug Resistance and Anti-cancer Drug Development and Screening
S4. Cancer Survivorship and Quality of Life
S5. Causes, Diagnosis and Treatment of Cancer
S6. Patterns and Treatment Consideration of Childhood Cancer
S7. Novel Methods and Technologies for Research and Treatment
Registration
The registration for The 5th International Electronic Conference on Cancers will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 7 June 2026.
Instructions for Authors
Important Deadlines
1. Deadline for abstract submission: 10 February 2026 15 March 2026.
2. Abstract acceptance notification:10 March 2026 12 April 2026.
Please note:
An abstract acceptance email only confirms that your abstract has been accepted. Oral or poster presentation invitations are determined separately by the conference chairs, and you will receive an additional email with the presentation result.
Abstract Requirements
1. Types of Submissions
- Accepted: Original research abstracts; systematic reviews or meta-analyses abstracts (must comply with PRISMA 2020).
- Not accepted: Narrative, scoping, comparative, perspective, opinion, or essay-style reviews
2. Content Requirements
- Length: 250–300 words
- Structure: Introduction, Methods, Results, Conclusions
- Language: Clear, publication-ready English
- Originality: Must be original and unpublished; previously published abstracts will not be considered
3. Authorship
- The submitting author must ensure all co-authors approve the content.
- Authors may submit multiple abstracts, but only one abstract per author may be selected for an oral presentation.
1. Each abstract must designate one presenter. To change the presenter, please contact us after you receive the oral/poster presentation invitation.
2. Only live presentations are accepted.
3. Presenters who do not attend the live session will not be eligible for awards or presentation certificates.
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session.
Authors are encouraged to prepare presentations using PowerPoint or equivalent software for online display alongside their abstract. If provided, slides will be presented directly on the conference website via the Sciforum.net slide viewer and should be prepared in the same format as a traditional conference presentation of research results. All slides must be converted to PDF format prior to submission to ensure accurate online display.
Each presentation should:
- Communicate the research question or objective, methodology, key results, and scientific novelty;
- Use a clear and logical structure, typically Introduction-Methods-Results&Discussion structure (IMRaD) or a field-appropriate alternative;
- Emphasize the relevance of the work;
- Support key findings with clear figures or tables where appropriate;
- Conclude with a critical interpretation of the results and their impact.
Posters should be designed to allow independent understanding of the research and clearly present the essential elements of the study.
Each poster should include:
- Title, authors, affiliations, and contact details (clearly displayed at the top);
- Brief introduction outlining the research objective;
- Concise methodology summary;
- Main results, supported by clear, well-labeled figures or tables where appropriate;
- Short conclusion summarizing key findings and their relevance.
Technical specifications:
Dimensions (cm): 84.1 × 118.9 (A0 - portrait)
Resolution: 300 dpi
Pixel size (portrait, 300 dpi): 9933 × 14043 px
Minimum font size: ≥24
The poster template can be downloaded HERE. We will reach out to you closer to the dates of the conference with more information.
Note: The uploaded poster may be used as provided and serves as a reference. However, as long as the technical specifications are followed, scholars are welcome to use any poster template of their choice.
It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue published in Cancers (ISSN: 2072-6694 , Impact Factor 4.4), with a 20% discount on the publication fee. Conference discounts cannot be combined with reviewer vouchers. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
Special Issue Submission Deadline: 30 June 2027
Accepted abstracts will be included in the conference report of the 5th International Electronic Conference on Cancers, published in the Medical Sciences Forum (ISSN: 2673-9992). Authors of accepted abstracts are highly encouraged to submit an extended proceeding paper (ideally 4-8 pages in length) for free, please submit it to the same journal after the conference.
Proceedings paper submission deadline: 27 July 2026.
Please click HERE to submit your proceedings paper to Medical Sciences Forum, and be sure to disclose the conference information in your cover letter or mention the conference name in your submission.
IECC 2026_proceeding_paper-template.dot
Publication Notice: Proceedings papers will undergo peer-review procedure. Acceptance at the conference does not ensure final publication.
Manuscripts for the proceedings issue must be formatted as follows:
Title;
Full author names;
Affiliations (including full postal address) and authors' e-mail addresses;
Abstract;
Keywords;
Introduction;
Methods;
Results and Discussion;
Conclusions;
Acknowledgements;
References.
Event Awards
The Awards
Number of Awards Available: 6
Eligibility: Open to all authors selected as oral speakers who have delivered their presentation. Failure to present, delegation of the presentation to another person, or use of AI-generated voice or similar substitutes will result in disqualification.
Criteria: Evaluation considers scientific rigor (clear, literature-supported research question or hypothesis, appropriate methodology, robust analysis and critical discussion of the results), IMRaD/field-appropriate structure, clarity of presented data (clear, well-labeled figures and tables), presentation skills and audience engagement, demonstrated scientific novelty and impact.
Prize: An award of CHF 200 and a certificate in recognition of your outstanding contribution.
Best Poster Award
Eligibility: Open to all authors who have presented their work through posters. Failure to present, delegation of the presentation to another person, or use of AI-generated voice or similar substitutes will result in disqualification.
Criteria: Evaluation considers scientific rigor (clear, literature-supported research question or hypothesis, appropriate methodology, robust analysis, and critical discussion of the results), IMRaD/field-appropriate structure enabling independent understanding, clarity of presented data (clear, well-labeled figures and tables), presentation skills (if orally presented), demonstrated scientific novelty and impact.
Prize: An award of CHF 200 and a certificate in recognition of your outstanding contribution.
Winner Announcement: The award winners will be evaluated and selected by the scientific committee after the conference. Results will be announced on the website and all winners will be individually contacted via email.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Conference Secretariat
Ms. Ann Li
Mr. Russell Wang
Ms. Chloe Lv
Email: iecc2026@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
